Better Results For Invega Over Seroquel Could Enhance J&J’s Bottom Line At AstraZeneca’s Expense
Invega could cut into Seroquel’s hefty share of “churn” segment of antipsychotic market.
Invega could cut into Seroquel’s hefty share of “churn” segment of antipsychotic market.